Iovance Biotherapeutics (IOVA) AI Stock Analysis

• Market Cap: $1.05B
• Dividend Yield: N/A
• Average Volume (3M): 13.69M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.09
• Revenue Growth: 11070.12%
• EPS Growth: 32.07%
• Country: US
• Employees: 838
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.36
• Shares Outstanding: 333,934,400
• 10 Day Avg. Volume: 19,309,877
• 30 Day Avg. Volume: 13,688,665
• PEG Ratio: -0.36
• Price to Book (P/B): 0.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.85
• Enterprise Value/Market Cap: 0.51
• Enterprise Value/Revenue: 1.06
• Enterprise Value/Gross Profit: 12.98
• Enterprise Value/Ebitda: -0.35
• 1Y Price Target: $9.30
• Price Target Upside: 134.26% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11

• Rating: 49 Neutral
• Price Target: $4.00 ▲(0.76%Upside)

Iovance Biotherapeutics presents a mixed investment case. While recent revenue growth and strategic corporate developments are promising, ongoing profitability challenges and valuation concerns weigh heavily. Technical indicators suggest the stock is overbought, and the earnings call highlighted both opportunities and ongoing operational issues.

Positive Factors

Clinical Efficacy

Commercial AMTAGVI demonstrates impressive clinical responses, particularly in earlier stage patients.

Investor Sentiment

Despite setback, there is significant market and value generating potential for AMTAGVI, and the positive results and KOL conversations at ASCO '25 help reaffirm that position.

Market Adoption

These data are a positive step towards achieving long-term objectives by expanding adoption among physicians and ATCs.

Negative Factors

Financial Performance

The stock has experienced negative pressure due to the lower than expected AMTAGVI revenue and downward revised financial guidance.

Operational Challenges

Operational and logistical challenges with ATCs have continued to persist one year+ into launch.

Regulatory Challenges

The FDA's complete response letter (CRL) regarding REPL's BLA for RP1 + nivolumab in advanced melanoma appears to require a significant amount of time and work to address.

Iovance Biotherapeutics Business Overview & Revenue Model

Company Description

Iovance Biotherapeutics, Inc. is a biotechnology company focused on the development and commercialization of innovative cancer immunotherapies. It operates within the healthcare and pharmaceuticals sector, specializing in cell therapy treatments. The company's core products are based on tumor-infiltrating lymphocyte (TIL) technology, which harnesses the power of a patient's immune cells to attack cancer cells, offering potential therapies for patients with various types of cancer including melanoma and cervical cancer.

How the Company Makes Money

Iovance Biotherapeutics generates revenue primarily through the development and potential commercialization of its proprietary TIL therapy products. The company's revenue model is based on bringing these therapies to market either independently or through partnerships with other pharmaceutical companies. Iovance may earn income through licensing agreements, collaboration with other firms, and potential future sales of approved therapies. Additionally, significant partnerships or alliances with larger pharmaceutical companies can provide funding, milestone payments, and royalties, contributing to its revenue streams.

Iovance Biotherapeutics Financial Statement Overview

Summary

Iovance Biotherapeutics is experiencing revenue growth but remains unprofitable with significant operational inefficiencies and negative cash flow. Despite a strong equity position and low leverage, the financial stability could be challenged by ongoing losses.

Income Statement

Iovance Biotherapeutics has shown substantial revenue growth with total revenue increasing significantly from $1.18 million in 2023 to $212.68 million in TTM (Trailing-Twelve-Months), marking its first substantial revenue generation. However, despite revenue growth, the company remains unprofitable with a negative net income of $375.36 million in TTM. The gross profit margin is 19.2% in TTM, reflecting that costs are still high relative to revenue. The EBIT and EBITDA margins are negative, indicating ongoing operational inefficiencies and high operating costs.

Balance Sheet

The balance sheet shows a relatively strong equity position, with a debt-to-equity ratio of 0.07, suggesting low leverage. Stockholders' equity stands at $767.87 million, indicating financial stability. However, the negative net income affects the return on equity, which remains negative. The equity ratio is 79.4%, reflecting a strong capital structure with substantial equity financing.

Cash Flow

The company has a negative operating cash flow of $334.39 million in TTM, demonstrating cash outflows from operations. Free cash flow also remains negative at $347.50 million, indicating challenges in generating cash from operations after capital expenditures. However, the firm successfully raised $340.40 million through financing activities, supporting its cash position.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	164.07M	1.19M	0.00	0.00	0.00
Gross Profit	40.08M	-9.57M	-21.14M	-13.98M	-8.71M
EBITDA	-351.67M	-427.43M	-374.76M	-328.27M	-250.87M
Net Income	-372.18M	-444.04M	-395.89M	-342.25M	-259.58M
Balance Sheet
Total Assets	910.43M	780.35M	663.98M	777.33M	768.46M
Cash, Cash Equivalents and Short-Term Investments	323.78M	279.87M	471.85M	596.00M	629.44M
Total Debt	58.26M	75.86M	84.45M	71.53M	51.66M
Total Liabilities	200.02M	195.74M	164.34M	155.67M	111.96M
Stockholders Equity	710.40M	584.61M	499.64M	621.66M	656.50M
Cash Flow
Free Cash Flow	-364.05M	-384.11M	-313.18M	-265.51M	-251.93M
Operating Cash Flow	-352.98M	-361.82M	-292.76M	-227.94M	-205.13M
Investing Cash Flow	-96.41M	-155.24M	256.45M	132.00K	-317.85M
Financing Cash Flow	390.66M	462.96M	190.15M	239.27M	576.42M

Iovance Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.97
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IOVA, the sentiment is Positive. The current price of 3.97 is above the 20-day moving average (MA) of 2.09, above the 50-day MA of 1.98, and below the 200-day MA of 5.36, indicating a neutral trend. The MACD of 0.27 indicates Negative momentum. The RSI at 83.51 is Negative, neither overbought nor oversold. The STOCH value of 88.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IOVA.

Iovance Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMTX	57 Neutral	$722.01M	53.85	-4.52%	―	92.31%	78.17%
AMLX	57 Neutral	$747.89M	―	-83.24%	―	-100.32%	-197.69%
VIR	56 Neutral	$792.10M	―	-44.59%	―	-73.79%	-5.24%
Sector *	50 Neutral	AU$2.60B	2.95	-57.47%	2.44%	36.73%	13.67%
IOVA	49 Neutral	$1.05B	―	-51.85%	―	11070.12%	32.07%
KALV	45 Neutral	$789.77M	―	-121.50%	―	―	-18.75%
NUVB	45 Neutral	$871.07M	―	-119.66%	―	―	-551.08%

Iovance Biotherapeutics Corporate Events

Iovance Biotherapeutics Appoints New Chief Financial Officer

On July 15, 2025, Iovance Biotherapeutics announced the appointment of Corleen Roche as Chief Financial Officer, effective August 6, 2025. Ms. Roche, who brings over 30 years of experience in the biotech and life sciences industry, will replace Matthew W. Rosinack. Her extensive background in executive financial leadership and product launches is expected to be invaluable as Iovance focuses on revenue growth and advancing its mission of developing novel therapies for cancer patients. This strategic appointment is seen as a significant step for Iovance as it navigates its first commercial launch and aims to strengthen its position in the biotechnology industry.

The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics CFO Resignation and Interim Appointment

On June 30, 2025, Iovance Biotherapeutics announced the resignation of Jean-Marc Bellemin as Chief Financial Officer, effective immediately, with Matthew W. Rosinack stepping in as interim Principal Financial Officer and Principal Accounting Officer. Rosinack, who has extensive experience in finance roles at various biotechnology and medical device companies, has been with Iovance since September 2021 and will temporarily fill the role as the company navigates this transition.

The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics CFO Resignation Announced

On June 10, 2025, Jean-Marc Bellemin, the Chief Financial Officer of Iovance Biotherapeutics, announced his resignation effective July 10, 2025, to pursue other opportunities. This departure may impact the company’s financial leadership and strategic direction as it continues to develop cancer immunotherapies.

The most recent analyst rating on (IOVA) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics Approves Key Proposals at Annual Meeting

On June 10, 2025, Iovance Biotherapeutics held its Annual Meeting of Stockholders virtually, where stockholders voted on five key proposals. These included the election of directors, approval of executive compensation, ratification of Ernst & Young LLP as the accounting firm, and amendments to increase shares in the equity incentive and employee stock purchase plans. All proposals were approved, reflecting strong shareholder support and potentially enhancing the company’s operational flexibility and strategic initiatives.

The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.